| Subject |
The board of directors of the Company approved removal of the noncompete clause for managers. |
- Date of the board of directors resolution: 2024/02/29
- Name and title of the managerial officer with permission to engage in competitive conduct: The general manager, Shu-ling Cheng.
- Items of competitive conduct in which the officer is permitted to engage:
- (1) Director of the Stemcyte TAIWAN CO., LTD.(Representative Director of the Diamond Biofund Inc.)
- (2) Director of the StemCyte International Ltd.(Representative Director of the Diamond Biofund Inc.)
- (3) Director of the ImmunAdd Inc.(Representative Director of the Diamond Biofund Inc.)
- Period of permission to engage in the competitive conduct: For the duration of employment as a manager of the Company.
- Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the Company Act): The board of directors approved the proposal unanimously with no changes.
- If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter “N/A” below): N/A
- Company name of the mainland China enterprise and the officer’s position in the enterprise: N/A
- Address of the mainland China enterprise: N/A
- Operations of the mainland China enterprise: N/A
- Impact on the company’s finance and business: N/A
- If the managerial officer or director has invested in the mainland China enterprise, the monetary amount of the investment and the officer or director’s shareholding ratio: N/A
- Any other matters that need to be specified: None.
|
